This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Recro Pharma Falls as FDA Denies Approval to Pain Candidate
by Zacks Equity Research
FDA issues complete response letter for Recro Pharma's (REPH) marketing application for pain candidate, meloxicam, for the second time.
Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan
by Zacks Equity Research
Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.
Dermira (DERM) Catches Eye: Stock Jumps 12%
by Zacks Equity Research
Dermira (DERM) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105
by Zacks Equity Research
Aerie (AERI) begins dosing in a phase II study on AR-1105 for treating patients with macular edema due to retinal vein occlusion.
ChemoCentryx (CCXI) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
ChemoCentryx (CCXI) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Karyopharm Stock Up Even as FDA Delays Selinexor NDA Verdict
by Zacks Equity Research
Karyopharm's (KPTI) stock rises despite the FDA's decision to delay the verdict on the NDA filing of selinexor, which is developed for treating patients with relapsed-refractory multiple myeloma.
Spectrum Pharma (SPPI) Withdraws Rolontis BLA, Shares Down
by Zacks Equity Research
Spectrum Pharma (SPPI) withdraws the BLA seeking approval for Rolontis, as the FDA requests for additional manufacturing-related data.
Top Ranked Momentum Stocks to Buy for March 6th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 6th
Amneal Pharmaceuticals (AMRX) Surges: Stock Moves 8.6% Higher
by Zacks Equity Research
Amneal Pharmaceuticals (AMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Zacks.com featured highlights include: Meet, Verint, First BanCorp, Sotherly and AIT
by Zacks Equity Research
Zacks.com featured highlights include: Meet, Verint, First BanCorp, Sotherly and AIT
5 Stocks With Recent Price Strength to Strengthen Portfolio
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.